Company Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.
The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Country | United States |
IPO Date | Dec 18, 2003 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 28 |
CEO | Yomara Gomez-Naiden |
Contact Details
Address: 11455 El Camino Real San Diego, California United States | |
Website | https://www.meipharma.com |
Stock Details
Ticker Symbol | MEIP |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001262104 |
CUSIP Number | 55279B202 |
ISIN Number | US55279B3015 |
Employer ID | 51-0407811 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Anne Frese | Chief People Officer |
David A. Walsey J.D., L.L.M. | Senior Vice President of Corporate Affairs |
Dr. Robert D. Mass | Strategic Advisor |
Nicole Chyoko Iida | Vice President of Legal Affairs |
Yomara Gomez-Naiden | Senior Vice President of Operations & Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 25, 2024 | 8-K | Current Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Oct 25, 2024 | 8-K | Current Report |
Sep 19, 2024 | 10-K | Annual Report |
Sep 19, 2024 | 8-K | Current Report |
Aug 02, 2024 | 8-K | Current Report |
Jul 30, 2024 | 8-K | Current Report |
Jul 22, 2024 | 8-K | Current Report |
Jun 25, 2024 | 8-K | Current Report |